Evidence map›Paper›PMID 29699374›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2018

Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells

Mahnaz Mohammadi Kian, Saeed Mohammadi, Mahmoud Tavallaei, Bahram Chahardouli, Saharbano Rostami, Mahdi Zahedpanah, Ardeshir Ghavamzadeh, Mohsen Nikbakht

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. The Question of Survival or Death: What Is the Role of Autophagy in Acute Myeloid Leukemia (AML)?International journal of hematology-oncology and stem cell research · 2022
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Curcumin Combined with Thalidomide Reduces Expression ofDrug design, development and therapy · 2020
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mahnaz Mohammadi KianHematology Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.Email: m-nikbakht@sina.tums.ac.ir, smohammadi@sina.tums.ac.ir
Saeed Mohammadi
Mahmoud Tavallaei
Bahram Chahardouli
Saharbano Rostami
Mahdi Zahedpanah
Ardeshir Ghavamzadeh
Mohsen Nikbakht
Tehran University of Medical Sciences · IRBaqiyatallah University of Medical Sciences · IRQazvin University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a blood disorder characterized by uncontrolled proliferation of myeloid progenitors and decrease in the apoptosis rate. The vascular endothelial growth factor (VEGF) promotes blood vessel regeneration which might play important roles in development and progression of neoplasia. Our previous studies focused on cytotoxicity and anticancer effects of arsenic trioxide (ATO) and thalidomide (THAL) as an anti-VEGF compound in the AML cell model. ATO also affects regulatory genes involved in cell proliferation and apoptosis. The aim of present study was to examine the effects of ATO and THAL alone and in combination on U937 and KG-1 cells , with attention to mRNA expression for VEGF isoforms. Growth inhibitory effects was assessed by MTT assay and apoptosis induction was determined by Annexin/PI staining. mRNA expression levels were evaluated by real-time PCR. Our data indicated that ATO (1.618μM and 1μM in KG-1 and U937 cell lines respectively), THAL (80μM and 60μM) and their combination inhibited proliferation and induced apoptosis in our cell lines. mRNA expression of VEGF (A, B) decreased while C and D isoforms did not show any significant changes. Taken together, according to the obtained results, the VEGF autocrine loop could be a target as a therapeutic strategy for cases of AML.

Indexed as

Antineoplastic AgentsApoptosisArsenicalsArsenic TrioxideCell Line, TumorCell ProliferationCell SurvivalHumansLeukemia, Myeloid, AcuteNeovascularization, PathologicOxidesThalidomideU937 CellsVascular Endothelial Growth FactorsAntineoplastic AgentsArsenicalsArsenic TrioxideOxidesThalidomideVascular Endothelial Growth Factorsacute myeloid leukemiaArsenic trioxideThalidomideVascular Endothelial Growth Factor (VEGF)

Identifiers

PMID29699374
PMCPMC6031772
OpenAlexW2803291593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.